A small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

Additional Information

Synonyms	AP 23573, MK-8669, Ridaforolimus
Product #	C-2285
CAS #	572924-54-0
Chemical Name	(1R,2R,4S)-4-((2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-DIHYDROXY-19,30-DIMETHOXY-15,17,21,23,29,35-HEXAMETHYL-2,3,10,14,20-PENTAOXO-11,36-DIOXA-4-AZATRICYCLO[30.3.1.04,9] HEXATRIACONTA-16,24,26,28-TETRAEN-12-YL]PROPYL)-2-METHOX
Formula	C53H84NO14P
MW	989.56
Appearance	White to off-white Solid
Purity	99% by HPLC
Solubility	DMSO
Storage Temp	-20°C
Therapeutic Area	Oncological Disorders
Use	A selective FRAP (mTOR) inhibitor use in cancer

Additional Information

MDL Number	MFCD13184816
ChemACX	X1722909-7
InChI	InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
SMILES	C[C@@H]1CCC2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OP(=O)(C)C)C)/C)O)OC)C)C)/C)OC